Pulse Biosciences (PLSE) Q4 2024 earnings summary

Executive summary

• New CEO Paul LaViolette highlighted the transition from clinical development to commercial growth, emphasizing the unique value and market potential of the nanosecond PFA technology platform.

• Advanced clinical programs in soft tissue and cardiac ablation, with positive feasibility data for thyroid nodules and atrial fibrillation (AF) treatment using nsPFA technology.

• The company is advancing three main programs: soft tissue ablation for benign thyroid disease, a surgical clamp for atrial fibrillation, and a 360 catheter for AF ablation.

• Expanded U.S. pilot and European feasibility studies, with pivotal U.S. trials for thyroid and cardiac ablation expected to begin mid-2025.

• Strengthened leadership with new CEO, CFO, and Chief Medical Officer appointments.

Financial highlights

• GAAP net loss for Q4 2024 was $19.4 million, up from $11.9 million in Q4 2023; non-GAAP net loss was $10.4 million, up from $8.3 million.

• Full-year 2024 GAAP net loss was $53.6 million, compared to $42.2 million in 2023; non-GAAP net loss was $36.9 million vs. $33.8 million prior year.

• GAAP costs and expenses for Q4 2024 rose to $20.3 million from $12.5 million year-over-year; full-year costs were $56.3 million, up from $43.6 million.

• Cash and cash equivalents as of December 31, 2024, totaled $118 million, up from $44.4 million a year earlier, bolstered by $47.9 million in net proceeds from warrant exercises.

• Cash used in operations for 2024 was $36.0 million, compared to $32.8 million in 2023.

Outlook and guidance

• Key 2025 priorities include commercializing the soft tissue ablation device for thyroid disease and initiating pivotal IDE studies for the cardiac 360 catheter and surgical clamp.

• U.S. clinical trials for thyroid and cardiac ablation systems expected to commence mid-2025, supporting future FDA submissions.

• Commercial launch of soft tissue ablation in the U.S. planned, with eight centers to begin use in coming months.

• Plans to expand clinical trials and pursue regulatory clearance for additional indications.

• Commercial team expansion and account development underway to drive adoption of the nsPFA system.